News & Views | Published:

A three-drug combination to treat BRAF-mutant cancers

Nature Medicine volume 23, pages 913914 (2017) | Download Citation

A new study that uses a triple-drug combination to overcome a major mechanism of drug resistance in cancer provides insights into the evolutionary paths taken by tumors in the face of selective pressure.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & Curr. Top. Microbiol. Immunol. 355, 83–98 (2010).

  2. 2.

    et al. Nat. Commun. 3, 724 (2012).

  3. 3.

    et al. N. Engl. J. Med. 371, 1867–1876 (2014).

  4. 4.

    et al. N. Engl. J. Med. 371, 1877–1888 (2014).

  5. 5.

    et al. Nat. Med. 23, 929–937 (2017).

  6. 6.

    & Nat. Rev. Cancer 12, 494–501 (2012).

  7. 7.

    , , & Br. J. Haematol. 165, 441–454 (2014).

  8. 8.

    et al. Nature 494, 251–255 (2013).

  9. 9.

    & Clin. Cancer Res. 23, 618–622 (2017).

  10. 10.

    , & Br. J. Cancer 111, 640–645 (2014).

Download references

Author information

Affiliations

  1. Ari J. Firestone and Jeff Settleman are at Calico Life Sciences, South San Francisco, California, USA.

    • Ari J Firestone
    •  & Jeff Settleman

Authors

  1. Search for Ari J Firestone in:

  2. Search for Jeff Settleman in:

Competing interests

A.J.F. and J.S. are both employees of Calico Life Sciences.

Corresponding author

Correspondence to Jeff Settleman.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm.4382

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing